Drugs that contain Ledipasvir; Sofosbuvir

1. List of Harvoni drug patents

HARVONI's oppositions filed in EPO
HARVONI Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

US10039779 GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jan, 2034

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8735372 GILEAD SCIENCES INC NA
Mar, 2028

(4 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8580765

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8735372

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Mar, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA
Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus
Sep, 2029

(6 years from now)

US8273341 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2031

(7 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates
Jun, 2031

(8 years from now)

US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US9393256

(Pediatric)

GILEAD SCIENCES INC Methods for treating HCV
Mar, 2033

(9 years from now)

US10039779

(Pediatric)

GILEAD SCIENCES INC Combination formulation of two antiviral compounds
Jul, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
ODE* (ODE*) Aug 28, 2026
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 4, 5 or 6 chronic hepatitis c virus (hcv) infection; For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) inf...

Dosage: TABLET;ORAL

More Information on Dosage

HARVONI family patents

81

United States

30

Japan

29

European Union

27

China

23

Korea, Republic of

19

Hong Kong

19

Taiwan, Province of China

17

Spain

16

Singapore

15

Canada

14

Israel

14

Mexico

14

Brazil

14

Portugal

14

New Zealand

EA

13

EA

12

Australia

12

Slovenia

12

Poland

11

Chile

10

Hungary

10

Argentina

9

Denmark

9

Croatia

9

Cyprus

8

South Africa

8

Lithuania

7

Uruguay

7

Colombia

7

Peru

6

Ecuador

6

RS

6

Ukraine

6

ME

5

Philippines

5

Costa Rica

4

Russia

4

Norway

4

Malaysia

4

San Marino

3

Germany

3

Moldova, Republic of

2

Morocco

AP

2

AP

2

Netherlands

1

Turkey

1

Luxembourg

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic